When a patent dispute over the rich rights to a human growth hormone ended four weeks ago in San Francisco federal court, the University of California staggered out bruised but largely victorious.

Jurors tossed out opponent Genentech Inc.’s claim that UC’s 1982 patent wasn’t enabled, or adequate for use by other scientists. And they deadlocked 8-1 in favor of UC’s claim that Genentech had infringed on the school’s patent.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]